Company Description
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States.
It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies.
In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes.
The company was founded in 1996 and is based in New York, New York.
| Country | United States |
| Founded | 1996 |
| IPO Date | Jun 16, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 89 |
| CEO | Pablo Legorreta |
Contact Details
Address: 110 East 59th Street New York, New York 10022 United States | |
| Phone | 212 883 0200 |
| Website | royaltypharma.com |
Stock Details
| Ticker Symbol | RPRX |
| Exchange | NASDAQ |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $28.00 |
| CIK Code | 0001802768 |
| CUSIP Number | G7709Q104 |
| ISIN Number | GB00BMVP7Y09 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Pablo Gerardo Legorreta | Founder, Chairman of the Board and Chief Executive Officer |
| Terrance P. Coyne | Executive Vice President and Chief Financial Officer |
| George Wingate Lloyd | Executive Vice President of Investments and Chief Legal Officer |
| Christopher Hite | Vice Chairman and Executive Vice President |
| Dr. Marshall Jonathan Urist M.D., Ph.D. | Executive Vice President of Research and Investments |
| Arthur Richard McGivern J.D. | Executive Vice President of Investments and General Counsel |
| Ashwin Pai M.D. | Executive Vice President of Investments |
| Kristin Stafford | Senior Vice President and Chief Accounting Officer |
| Eric Cornelius Schneider | Senior Vice President and Chief Technology Officer |
| Dr. James Folmar Reddoch Ph.D. | Executive Vice President of Investments and Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 17, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jan 16, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jan 15, 2025 | 425 | Filing |
| Jan 13, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jan 13, 2025 | 8-K | Current Report |
| Jan 10, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jan 10, 2025 | 8-K | Current Report |
| Jan 10, 2025 | 8-K | Current Report |
| Dec 31, 2024 | 8-K | Current Report |
| Nov 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |